Advice for Enhancing the Client–Sponsor Relationship - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Advice for Enhancing the Client–Sponsor Relationship
Key talks from the recent PDA/FDA regulatory conference highlight room for improvement.

Pharmaceutical Technology
Volume 36, Issue 11, pp. 76,78-79

Allan Coukell, director of the Medical Programs Pew Health Group at The Pew Charitable Trusts, provided a global perspective on this issue. He pointed out that outsourcing has grown exponentially over the past 10 years, complicating the already complicated pharmaceutical supply chain. In discussing this complexity, he brought to light some disturbing facts, including that FDA 483 observations to contract manufacturers have risen over the past three years. In addition, Coukell noted that "FDA has expressed concerns about deficiencies in supplier qualification programs and quality agreements and that current regulations do not require companies to assess supplier plants before purchasing ingredients from them, or to visit the plants at any time to ensure quality standards are in place." He further highlighted the steps being taken to address this gap in regulations through the passage of new laws such as the 2012 FDA Safety and Innovation Act (FDASIA) and Generic Drug User Fee Amendment (GDUFA). He also complimented industry on some of its initiatives aimed at resolving supply-chain issues, including the efforts of Rx-360 (the international pharmaceutical supply chain consortium), EXCiPACT (a voluntary international scheme to provide independent third-party certification of manufacturers, suppliers, and distributors of pharmaceutical excipients worldwide), and International Pharmaceutical Excipient Auditing (IPEA), which also provides third-party audits through a shared audit program and ANSI accredited certification program.

It is important for industry to understand and work to improve their client–service provider relationships. Such re-evaluations make both sponsors and CMOs more effective in achieving the goal of improving public health and safety.

Susan J. Schniepp is vice-president of Quality and Regulatory Affairs at Allergy Laboratories, Oklahoma City, OK 73109. Tel. 405.235.1451,


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here